Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission

BackgroundMicrobicides must protect against STD pathogens without causing unacceptable toxic effects. Microbicides based on nonoxynol-9 (N9) and other detergents disrupt sperm, HSV and HIV membranes, and these agents are effective contraceptives. But paradoxically N9 fails to protect women against HIV and other STD pathogens, most likely because it causes toxic effects that increase susceptibility. The mouse HSV-2 vaginal transmission model reported here: (a) Directly tests for toxic effects that increase susceptibility to HSV-2, (b) Determines in vivo whether a microbicide can protect against HSV-2 transmission without causing toxicities that increase susceptibility, and (c) Identifies those toxic effects that best correlate with the increased HSV susceptibility.MethodsSusceptibility was evaluated in progestin-treated mice by delivering a low-dose viral inoculum (0.1 ID50) at various times after delivering the candidate microbicide to detect whether the candidate increased the fraction of mice infected. Ten agents were tested – five detergents: nonionic (N9), cationic (benzalkonium chloride, BZK), anionic (sodium dodecylsulfate, SDS), the pair of detergents in C31G (C14AO and C16B); one surface active agent (chlorhexidine); two non-detergents (BufferGel®, and sulfonated polystyrene, SPS); and HEC placebo gel (hydroxyethylcellulose). Toxic effects were evaluated by histology, uptake of a 'dead cell' dye, colposcopy, enumeration of vaginal macrophages, and measurement of inflammatory cytokines.ResultsA single dose of N9 protected against HSV-2 for a few minutes but then rapidly increased susceptibility, which reached maximum at 12 hours. When applied at the minimal concentration needed for brief partial protection, all five detergents caused a subsequent increase in susceptibility at 12 hours of ~20–30-fold. Surprisingly, colposcopy failed to detect visible signs of the N9 toxic effect that increased susceptibility at 12 hours. Toxic effects that occurred contemporaneously with increased susceptibility were rapid exfoliation and re-growth of epithelial cell layers, entry of macrophages into the vaginal lumen, and release of one or more inflammatory cytokines (Il-1β, KC, MIP 1α, RANTES). The non-detergent microbicides and HEC placebo caused no significant increase in susceptibility or toxic effects.ConclusionThis mouse HSV-2 model provides a sensitive method to detect microbicide-induced toxicities that increase susceptibility to infection. In this model, there was no concentration at which detergents provided protection without significantly increasing susceptibility.

[1]  D. Bernstein,et al.  Evaluations of Unformulated and Formulated Dendrimer-Based Microbicide Candidates in Mouse and Guinea Pig Models of Genital Herpes , 2003, Antimicrobial Agents and Chemotherapy.

[2]  M. Bowden,et al.  Microbicides--evaluating multiple formulations of C31G. , 2002, Contraception.

[3]  F. Krebs,et al.  Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G. , 2005, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  R. Doms,et al.  Use of a Small Molecule CCR5 Inhibitor in Macaques to Treat Simian Immunodeficiency Virus Infection or Prevent Simian–Human Immunodeficiency Virus Infection , 2003, The Journal of experimental medicine.

[5]  K. Barnhart,et al.  In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. , 2004, Contraception.

[6]  K. Barnhart,et al.  Magnetic resonance imaging to determine the distribution of a vaginal gel: before, during, and after both simulated and real intercourse. , 2002, Contraception.

[7]  K. Whaley,et al.  Nonoxynol-9 protects mice against vaginal transmission of genital herpes infections. , 1993, The Journal of infectious diseases.

[8]  P. Spear,et al.  Disruption of Adherens Junctions Liberates Nectin-1 To Serve as Receptor for Herpes Simplex Virus and Pseudorabies Virus Entry , 2002, Journal of Virology.

[9]  D. Phillips,et al.  Nonoxynol-9 causes rapid exfoliation of sheets of rectal epithelium. , 2000, Contraception.

[10]  A. Ashkar,et al.  Progesterone Increases Susceptibility and Decreases Immune Responses to Genital Herpes Infection , 2003, Journal of Virology.

[11]  S. Hillier,et al.  The Vaginal Microflora of Pig‐Tailed Macaques and the Effects of Chlorhexidine and Benzalkonium on This Ecosystem , 1996, Sexually transmitted diseases.

[12]  C. Lee Review: in vitro spermicidal tests. , 1996, Contraception.

[13]  D. Anderson,et al.  The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. , 2001, The Journal of infectious diseases.

[14]  John P. Moore,et al.  Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120 , 2003, Nature Medicine.

[15]  K. Barnhart,et al.  Distribution of a spermicide containing Nonoxynol-9 in the vaginal canal and the upper female reproductive tract. , 2001, Human reproduction.

[16]  D. Phillips,et al.  Sulfated polysaccharides block chlamydia infection in vitro, but do not protect mice from vaginal inoculation. , 1998, Microbial pathogenesis.

[17]  K. Whaley,et al.  Residence half-life of IgG administered topically to the mouse vagina. , 1996, Biology of reproduction.

[18]  Fred Hendrikse,et al.  Monitoring of rabbit cornea response to dehydration stress by optical coherence tomography. , 2004, Investigative ophthalmology & visual science.

[19]  H. Rees,et al.  Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial , 2002, The Lancet.

[20]  S. Hillier,et al.  Effects of Nonoxynol‐9 on Vaginal Microflora and Chlamydial Infection in a Monkey Model , 1996, Sexually transmitted diseases.

[21]  P. Sen,et al.  Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model , 2001, AIDS.

[22]  K. Barnhart,et al.  Lesson learned and dispelled myths: three-dimensional imaging of the human vagina. , 2004, Fertility and sterility.

[23]  G. Doncel,et al.  In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. , 2005, AIDS research and human retroviruses.

[24]  N. Padian,et al.  Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices , 2001, AIDS.

[25]  L. Stanberry,et al.  Entry of Inflammatory Cells Into the Mouse Vagina Following Application of Candidate Microbicides: Comparison of Detergent-Based and Sulfated Polymer–Based Agents , 2002, Sexually transmitted diseases.

[26]  A. Clegg,et al.  The inhibitory effect of spermicidal agents on replication of HSV-2 and HIV-1 in-vitro. , 1993, The Journal of antimicrobial chemotherapy.

[27]  E. De Clercq,et al.  Effect of polyanionic compounds on intracutaneous and intravaginal herpesvirus infection in mice: impact on the search for vaginal microbicides with anti-HIV activity. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[28]  O. Laeyendecker,et al.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.

[29]  D. Phillips,et al.  Nonoxynol-9 enhances rectal infection by herpes simplex virus in mice. , 1998, Contraception.

[30]  D. Bernstein,et al.  The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model. , 1999, The Journal of infectious diseases.

[31]  F. Krebs,et al.  Comparative Safety Evaluation of the Candidate Vaginal Microbicide C31G , 2005, Antimicrobial Agents and Chemotherapy.

[32]  A. Iwasaki,et al.  In Vivo Role of Nectin-1 in Entry of Herpes Simplex Virus Type 1 (HSV-1) and HSV-2 through the Vaginal Mucosa , 2004, Journal of Virology.

[33]  F. Krebs,et al.  Mouse Model of Cervicovaginal Toxicity and Inflammation for Preclinical Evaluation of Topical Vaginal Microbicides , 2004, Antimicrobial Agents and Chemotherapy.

[34]  P. Spear,et al.  Herpes simplex virus: receptors and ligands for cell entry , 2004, Cellular microbiology.

[35]  K. Whaley,et al.  Microbicide Efficacy and Toxicity Tests in a Mouse Model for Vaginal Transmission of Chlamydia trachomatis , 2002, Sexually transmitted diseases.

[36]  K. Barnhart,et al.  Disruption of the upper female reproductive tract epithelium by nonoxynol-9. , 2003, Contraception.

[37]  E. Clercq,et al.  Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. , 1997, General pharmacology.

[38]  F. Krebs,et al.  A Broad-Spectrum Microbicide with Virucidal Activity against Sexually Transmitted Viruses , 1999, Antimicrobial Agents and Chemotherapy.

[39]  G. Rutherford,et al.  Nonoxynol-9 for preventing vaginal acquisition of sexually transmitted infections by women from men. , 2002, Cochrane Database of Systematic Reviews.

[40]  M. Bajpai,et al.  Interleukin (IL)-1, IL-6, and IL-8 Predict Mucosal Toxicity of Vaginal Microbicidal Contraceptives1 , 2004, Biology of reproduction.

[41]  S. S. Olmsted,et al.  Tests of BufferGel for Contraception and Prevention of Sexually Transmitted Diseases in Animal Models , 2001, Sexually transmitted diseases.

[42]  E. Raymond,et al.  Contraceptive Effectiveness and Safety of Five Nonoxynol-9 Spermicides: A Randomized Trial , 2004, Obstetrics and gynecology.

[43]  T. Quinn,et al.  The Effects of Herpes Simplex Virus-2 on HIV-1 Acquisition and Transmission: A Review of Two Overlapping Epidemics , 2004, Journal of acquired immune deficiency syndromes.

[44]  K. Whaley,et al.  Tests of vaginal microbicides in the mouse genital herpes model. , 1997, Contraception.

[45]  N. Bourne,et al.  Poly(sodium 4-styrene sulfonate): evaluation of a topical microbicide gel against herpes simplex virus type 2 and Chlamydia trachomatis infections in mice. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[46]  A. Gettie,et al.  Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. , 1998, AIDS research and human retroviruses.

[47]  G. Dickinson,et al.  Sensitivity testing of Pseudomonas aeruginosa to ciprofloxacin: comparison of the modified Stokes' method with MIC results obtained by the Etest. , 1999, The Journal of antimicrobial chemotherapy.

[48]  Naomi Bergman,et al.  Comparison of Microbicides for Efficacy in Protecting Mice Against Vaginal Challenge With Herpes Simplex Virus Type 2, Cytotoxicity, Antibacterial Properties, and Sperm Immobilization , 2001, Sexually transmitted diseases.

[49]  F. Krebs,et al.  Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate. , 1999, Antiviral research.

[50]  D. Phillips,et al.  Lubricants containing N-9 may enhance rectal transmission of HIV and other STIs. , 2004, Contraception.

[51]  K. Schneweis,et al.  Pathogenesis of genital herpes simplex virus infection in mice , 1984, Medical Microbiology and Immunology.